Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 105 results:
Συντάκτης Τίτλος Τύπος [ Έτος![(Desc)](https://www.med.auth.gr/sites/all/modules/biblio/misc/arrow-desc.png)
Φίλτρα: Συντάκτης is Katsiki, Niki [Clear All Filters]
Characteristics other than the diagnostic criteria associated with metabolic syndrome: an overview..
Curr Vasc Pharmacol. 12(4), 627-41.
(2014). Editorial: (New drug (LCZ696) for the treatment of heart failure with reduced ejection fraction after 10 years. Can one study change the guidelines?)..
Curr Vasc Pharmacol. 12(6), 867-9.
(2014). Editorial: (Persistent elevation of blood pressure in children and adolescents is associated with arterial hypertension and premature atherosclerosis in adults. Is it possible to reverse this?)..
Curr Vasc Pharmacol. 12(6), 870-2.
(2014). Effect of rosuvastatin on non-alcoholic steatohepatitis in patients with metabolic syndrome and hypercholesterolaemia: a preliminary report..
Curr Vasc Pharmacol. 12(3), 505-11.
(2014). Effect of Statins on rates of Long-Term Cardiovascular Events and Restenosis Following Carotid Endarterectomy..
Curr Vasc Pharmacol.
(2014). Effects of renin-angiotensin-aldosterone system inhibitors and beta-blockers on markers of arterial stiffness..
J Am Soc Hypertens. 8(2), 74-82.
(2014). Gene polymorphisms and thyroid function in patients with heart failure..
Endocrine. 45(1), 46-54.
(2014). Metabolic syndrome and non-cardiac vascular diseases: an update from human studies..
Curr Pharm Des. 20(31), 4944-52.
(2014). Metabolic syndrome in clinical practice..
Cardiol J. 21(2), 209.
(2014). Novel data on the pathogenesis of atherosclerosis, treatment targets, and new therapeutic interventions in lipid-related cardiovascular risk factors..
Curr Pharm Des. 20(40), 6215-9.
(2014). Peripheral artery disease in patients with type 2 diabetes..
J Diabetes Complications. 28(6), 912.
(2014). Prehypertension and the cardiometabolic syndrome: targeting several risk factors to achieve maximum benefit..
Expert Rev Cardiovasc Ther. 12(3), 295-6.
(2014). Reaching hypertriglyceridemia goals..
Curr Med Res Opin. 30(3), 391-3.
(2014). Renal denervation: transition from pathophysiology to clinical practice..
Angiology. 65(9), 760-8.
(2014). The role of statins in the treatment of type 2 diabetes mellitus: an update..
Curr Pharm Des. 20(22), 3665-74.
(2014). Should we expand the concept of coronary heart disease equivalents?.
Curr Opin Cardiol. 29(4), 389-95.
(2014). Treating heart failure with preserved ejection fraction: statins could make the difference..
Angiology. 65(4), 328-9.
(2014). Undertreatment of dyslipidemia: from the Arabian Gulf to the USA. Time to solve this problem!.
Curr Med Res Opin. 30(12), 2425-8.
(2014). Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update..
World J Gastroenterol. 21(22), 6820-34.
(2015). Contrast-Induced Nephropathy: An "All or None" Phenomenon?.
Angiology. 66(6), 508-13.
(2015). Editorial: effect of statins on rates of long-term cardiovascular events and restenosis following carotid endarterectomy..
Curr Vasc Pharmacol. 13(2), 223-5.
(2015). Editorial: microRNAs: Potential Targets for the Treatment of Cardiovascular Disease..
Curr Vasc Pharmacol. 13(3), 366-7.
(2015). Health benefits of the Mediterranean Diet: an update of research over the last 5 years..
Angiology. 66(4), 304-18.
(2015). High-intensity statin therapy and regression of coronary atherosclerosis in patients with diabetes mellitus..
J Diabetes Complications. 29(1), 142-5.
(2015). Hyperuricemia as a risk factor for cardiovascular disease..
Expert Rev Cardiovasc Ther. 13(1), 19-20.
(2015).